Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vimian Group AB ( (SE:VIMIAN) ) has shared an announcement.
Vimian Group AB has announced that Magnus Kjellberg, Head of its Specialty Pharma segment and a long-standing member of the group management team, will step down during spring 2026 to pursue opportunities outside the company. Kjellberg has been credited with helping build Vimian’s global Specialty Pharma platform in animal health, combining acquisition-led and organic growth, and the company emphasizes that the segment is now in a strong position for continued success; CFO Carl-Johan Zetterberg Boudrie will assume the role of interim Head of Specialty Pharma while a search for a permanent successor begins, with a transition period planned to ensure operational continuity and stability for stakeholders.
The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian Group AB is a global animal health company operating across four key areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. Headquartered in Stockholm, Sweden, it serves over 17,000 veterinary clinics and laboratories in more than 80 markets, employing around 1,200 people and generating annual revenues of approximately EUR 375 million by bringing innovative animal health solutions to professionals and pet owners worldwide.
YTD Price Performance: 7.19%
Average Trading Volume: 272,306
Technical Sentiment Signal: Hold
Current Market Cap: SEK17.1B
For an in-depth examination of VIMIAN stock, go to TipRanks’ Overview page.